Airsculpt Technologies (AIRS) stock price is $1.25, down 2.35% on the day, as of Oct 19, 2026. It has a market cap of $88.13Mn, and is classified in the Healthcare Services industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap88.13 Mn
P/E-7.51
P/S0.58
Div. Yield0.00
Total Debt (Qtr)43.57 Mn
Revenue Growth (1y) (Qtr)-2.53
Add ratio to table…
About
AirSculpt Technologies, Inc. provides a next generation body contouring treatment that removes fat and tightens skin through a minimally invasive procedure. The procedure uses a patented device that moves a cannula at high speed in a corkscrew motion to extract fat cells while simultaneously coagulating tissue to improve skin tone. Patients remain awake during the treatment which eliminates the need for general anesthesia and reduces recovery time. The company offers a broad…
AirSculpt Technologies, Inc. provides a next generation body contouring treatment that removes fat and tightens skin through a minimally invasive procedure. The procedure uses a patented device that moves a cannula at high speed in a corkscrew motion to extract fat cells while simultaneously coagulating tissue to improve skin tone. Patients remain awake during the treatment which eliminates the need for general anesthesia and reduces recovery time. The company offers a broad suite of services including traditional fat removal, fat transfer using the patient’s own tissue and dedicated skin tightening applications. Fat transfer procedures are marketed under names such as Power BBL for buttock enhancement and Up a Cup for breast augmentation. Skin tightening options include the AirSculpt Plus system that combines helium gas and radiofrequency energy and the AirSculpt Smooth device cleared for cellulite reduction. All services are delivered in company owned clinics that are styled to resemble upscale spas with private treatment rooms and lounging areas. AirSculpt Technologies, Inc. was founded in 2012 and has expanded to operate a network of locations across the United States and Canada.
Revenue is generated primarily from fees charged for each body contouring procedure performed at the company’s centers. The firm reports an average revenue per case of approximately twelve thousand eight hundred dollars based on its latest fiscal year. In addition to the core fat removal treatment the company sells complementary procedures such as AirSculpt Plus and AirSculpt Smooth which are priced separately. Patients typically pay the full amount at the time of booking and the business does not accept insurance reimbursement. To improve accessibility the company partners with third party financing firms that offer payment plans to consumers while assuming all credit risk. These financing arrangements allow a significant portion of the clientele to undergo treatment without paying the entire sum up front although the provider receives guaranteed payment from the finance company. The business also derives limited income from the sale of branded merchandise and educational content but this represents a minor fraction of total sales. Overall the company’s revenue model relies on high margin outpatient procedures with predictable cash collection.
AirSculpt Technologies, Inc. operates within the large and expanding market for body fat reduction that includes both surgical and non surgical alternatives. Surgical competitors consist of traditional liposuction providers and abdominoplasty specialists who often require general anesthesia and longer downtime. Non surgical rivals encompass devices that use cooling laser or ultrasound energy to destroy fat cells but frequently deliver modest and uneven results. The company distinguishes itself through a proprietary technique that removes fat while tightening skin in a single session without the need for stitches or anesthesia. This approach leads to less bruising faster recovery and a more natural appearance compared with conventional methods. In addition to technology the firm emphasizes a premium patient experience marked by upscale clinic decor personalized concierge service and strong surgeon expertise. Brand visibility is reinforced by a extensive library of before and after photographs active social media channels and partnerships with influencers and celebrities. These factors collectively enable AirSculpt to command higher prices and maintain a loyal customer base despite the presence of many lower cost entrants.
The company serves individual consumers who seek aesthetic improvement of areas such as the abdomen thighs buttocks and breasts. Its clientele includes both men and women typically ranging in age from twenty five to fifty five years old. Patients generally possess disposable income that permits them to spend on elective cosmetic procedures and often reside in affluent metropolitan and suburban neighborhoods. Geographic reach spans twenty states in the United States plus several provinces in Canada with clinics located near high end retail districts and lifestyle centers. While specific customer names are not disclosed the base consists of private individuals who pay out of pocket for treatments rather than relying on third party payers. Repeat business is common as many clients return for additional procedures on different body parts after experiencing initial results. The firm also notes that a growing segment of its audience comprises people who have undergone weight loss medication treatments and now seek skin tightening or contouring to address residual fat deposits. Overall the customer base is characterized by individuals who value discretion comfort and measurable aesthetic outcomes.
Sectors:Healthcare·Consumer DiscretionarySector rationaleThe company's primary revenue is generated from minimally invasive medical procedures (fat removal and skin tightening) performed using patented medical devices in clinics, which falls under Healthcare Services. A secondary sector of Consumer Discretionary is justified because the services are elective, non-essential aesthetic cosmetic procedures marketed to affluent consumers as a luxury experience, similar to high-end spas.Industries:Healthcare ServicesHealthcare ServicesPrimaryAirSculpt operates a network of company-owned clinics where it delivers minimally invasive body contouring, fat removal, and skin tightening procedures. These are outpatient healthcare services provided in a clinic setting, with revenue generated from per-procedure fees charged to patients.Personal ServicesPersonal ServicesSecondaryThe company's services are elective cosmetic procedures marketed as aesthetic improvements for consumers with disposable income, and the clinics are styled as upscale spas to provide a premium personal care experience.Classified using BQ-MICSCIK: 0001870940
Bull & bear
Investment Thesis
▲ Bull case
AirSculpt's strategic pivot toward GLP-1-driven aesthetic procedures represents an underappreciated catalyst that the market is overlooking, as the company has successfully monetized the post-weight-loss skin laxity opportunity that competitors are slower to address. While the market focuses on near-term revenue volatility from macroeconomic headwinds, AirSculpt has already rolled out stand-alone skin tightening to all centers and completed over 100 skin removal surgeries in Q4 2025 alone, with ramp-up expected across all locations in 2026. This expansion leverages existing infrastructure and talent, meaning incremental margins on these high-demand procedures could be substantially higher than core body contouring services. The American Society of Plastic Surgeons data cited by management indicates the skin tightening and removal market is as large as fat removal in procedure volume, implying a long-term $100 million-plus sales opportunity that is not yet reflected in current valuation multiples. Furthermore, the company's enhanced marketing strategy—including connected TV, influencer engagement, and targeted campaigns—is directly contributing to improved lead and consult volumes that are converting into revenue, with trends showing sequential improvement from down 22% at the start of 2025 to positive same-store sales growth by February 2026. This turnaround in core demand trends, coupled with the rollout of GLP-1-adjacent services, suggests the market is underestimating the inflection point in customer acquisition and procedure mix shift toward higher-margin offerings. Management's discipline in maintaining full upfront payment for financed procedures also reduces receivables risk while supporting conversion, a nuance often missed in consumer discretionary analyses. The combination of stabilized operations, proven demand for new services, and a scalable go-to-market engine positions AirSculpt to exceed its modest 2026 revenue guidance of $151 million to $157 million, particularly if skin removal procedures achieve broader adoption faster than anticipated.
AirSculpt's balance sheet restructuring and operational efficiency gains are creating a latent financial flexibility that the market is failing to price in, as the company has deleveraged meaningfully while simultaneously investing in growth-capable initiatives without sacrificing margin expansion. Over the last five quarters, AirSculpt repaid over $30 million of debt, reducing leverage below 2.5x as of the current date, and generated over $4 million in annualized savings from cost initiatives in 2025—savings that are being selectively reinvested into growth initiatives like the GLP-1 service expansion and enhanced marketing. Despite these reinvestments, the company delivered Q4 2025 adjusted EBITDA of $2.5 million (7.4% margin), up $0.6 million and 2.8 percentage points year-over-year, driven by gross margin expansion to approximately 59% and operational leverage in SG&A, which declined by $5 million versus the prior year quarter. This demonstrates that cost discipline is not merely defensive but is enabling operational leverage that falls directly to the bottom line as revenue stabilizes and grows. The CFO's background in leading a turnaround at Inspirato—where he improved margins and restored profitability prior to a take-private at a 50% premium—suggests a credible path to similar value creation here, especially as the company targets refinancing its term loan to maintain leverage below 2.5x while continuing to reinvest in de novos and geographic expansion. The market's focus on the delayed 10-K filing and immaterial accounting corrections overlooks the substantive progress in financial controls and cash flow generation, with operating cash flow at $3.1 million for the year despite lower revenue, indicating improving working capital management. This financial resilience, combined with a brand positioned to capture a growing aesthetics submarket, creates a scenario where AirSculpt could deliver margin expansion and free cash flow generation that exceeds current expectations, particularly if same-store sales momentum accelerates through the year as management anticipates.
AirSculpt's strategic pivot toward GLP-1-driven aesthetic procedures represents an underappreciated catalyst that the market is overlooking, as the company has successfully monetized the post-weight-loss skin laxity opportunity that competitors are slower to address. While the market focuses on near-term revenue volatility from macroeconomic headwinds, AirSculpt has already rolled out stand-alone skin tightening to all centers and completed over 100 skin removal surgeries in Q4 2025 alone, with ramp-up expected across all locations in 2026. This expansion leverages existing infrastructure and talent, meaning incremental margins on these high-demand procedures could be substantially higher than core body contouring services. The American Society of Plastic Surgeons data cited by management indicates the skin tightening and removal market is as large as fat removal in procedure volume, implying a long-term $100 million-plus sales opportunity that is not yet reflected in current valuation multiples. Furthermore, the company's enhanced marketing strategy—including connected TV, influencer engagement, and targeted campaigns—is directly contributing to improved lead and consult volumes that are converting into revenue, with trends showing sequential improvement from down 22% at the start of 2025 to positive same-store sales growth by February 2026. This turnaround in core demand trends, coupled with the rollout of GLP-1-adjacent services, suggests the market is underestimating the inflection point in customer acquisition and procedure mix shift toward higher-margin offerings. Management's discipline in maintaining full upfront payment for financed procedures also reduces receivables risk while supporting conversion, a nuance often missed in consumer discretionary analyses. The combination of stabilized operations, proven demand for new services, and a scalable go-to-market engine positions AirSculpt to exceed its modest 2026 revenue guidance of $151 million to $157 million, particularly if skin removal procedures achieve broader adoption faster than anticipated.
AirSculpt's balance sheet restructuring and operational efficiency gains are creating a latent financial flexibility that the market is failing to price in, as the company has deleveraged meaningfully while simultaneously investing in growth-capable initiatives without sacrificing margin expansion. Over the last five quarters, AirSculpt repaid over $30 million of debt, reducing leverage below 2.5x as of the current date, and generated over $4 million in annualized savings from cost initiatives in 2025—savings that are being selectively reinvested into growth initiatives like the GLP-1 service expansion and enhanced marketing. Despite these reinvestments, the company delivered Q4 2025 adjusted EBITDA of $2.5 million (7.4% margin), up $0.6 million and 2.8 percentage points year-over-year, driven by gross margin expansion to approximately 59% and operational leverage in SG&A, which declined by $5 million versus the prior year quarter. This demonstrates that cost discipline is not merely defensive but is enabling operational leverage that falls directly to the bottom line as revenue stabilizes and grows. The CFO's background in leading a turnaround at Inspirato—where he improved margins and restored profitability prior to a take-private at a 50% premium—suggests a credible path to similar value creation here, especially as the company targets refinancing its term loan to maintain leverage below 2.5x while continuing to reinvest in de novos and geographic expansion. The market's focus on the delayed 10-K filing and immaterial accounting corrections overlooks the substantive progress in financial controls and cash flow generation, with operating cash flow at $3.1 million for the year despite lower revenue, indicating improving working capital management. This financial resilience, combined with a brand positioned to capture a growing aesthetics submarket, creates a scenario where AirSculpt could deliver margin expansion and free cash flow generation that exceeds current expectations, particularly if same-store sales momentum accelerates through the year as management anticipates.
AirSculpt's reliance on GLP-1-driven demand introduces significant execution and competitive risks that the market is underestimating, as the company's ability to convert post-weight-loss patients into repeat aesthetic procedure recipients remains unproven at scale and vulnerable to shifting patient preferences or payer dynamics. While management highlights skin tightening and removal as a $100 million-plus opportunity, the procedures are still in early rollout phase—with only a pilot for skin excision completed in Q4 2025 and stand-alone skin tightening deployed in the second half of 2025—meaning revenue contribution remains minimal and uncertain. The assumption that GLP-1 users will seek these specific aesthetic services assumes a durable behavioral shift, yet there is no evidence that patients maintain long-term engagement with aesthetic providers post-weight loss, especially if they achieve their goals or face side effects from medication. Furthermore, the aesthetics industry is highly fragmented with low barriers to entry, and competitors—including medspas, plastic surgery clinics, and new entrants—are rapidly adopting similar GLP-1-adjacent service offerings, potentially eroding AirSculpt's first-mover advantage. The company's marketing spend, while enhanced, is still tied to discretionary consumer spending, which remains sensitive to economic downturns, and the fact that 50% of patients use third-party financing (with full upfront payment to AirSculpt but recourse risk to lenders) suggests underlying affordability constraints that could worsen if interest rates remain elevated or consumer confidence declines. The guidance for Q1 2026 revenue indicating a slight year-over-year decline, despite full-year expectations of modest growth, implies a back-end loaded recovery that may not materialize if seasonal trends or external shocks disrupt the anticipated inflection point.
AirSculpt's operational turnaround remains fragile and dependent on sustained cost discipline that may not be durable, as the company's recent margin improvements are largely driven by one-time SG&A reductions rather than structural revenue growth, leaving it vulnerable to margin compression if topline expansion stalls. The Q4 2025 adjusted EBITDA increase of $0.6 million was driven by gross margin expansion (to ~59%) and a $5 million decline in SG&A—largely from cost initiatives taken throughout 2025—yet revenue still declined 15% year-over-year and 16% on a same-store basis, indicating that the business is not yet generating organic growth at the center level. While management cites improved lead and consult volumes converting to revenue, the lack of specific metrics on conversion rates or average transaction size leaves room for skepticism about the sustainability of the volume trend. The decision to pause de novo center openings in 2026 to focus on existing base growth tacitly acknowledges uncertainty in replicating unit-level economics at new locations, and the exit of the sole international clinic (London) underscores challenges in scaling beyond the current footprint. Furthermore, the helium plasma supply constraint—where a meaningful portion of global supply is offline due to the Iran conflict—poses a tangible risk to the core skin tightening service, which management acknowledges they are monitoring but have not quantified in terms of potential downtime or cost impact. The company's leverage ratio, while improved to below 2.5x, remains dependent on continued debt paydown and refinancing success, and any delay in securing favorable terms could strain liquidity, especially given that cash flow from operations was only $3.1 million for the full year 2025 versus $11.4 million in 2024. This weak cash generation, combined with a business model that requires upfront investment in marketing and talent to drive volume, creates a scenario where AirSculpt could struggle to fund both balance sheet repair and growth initiatives simultaneously if revenue momentum fails to accelerate as expected.
AirSculpt's reliance on GLP-1-driven demand introduces significant execution and competitive risks that the market is underestimating, as the company's ability to convert post-weight-loss patients into repeat aesthetic procedure recipients remains unproven at scale and vulnerable to shifting patient preferences or payer dynamics. While management highlights skin tightening and removal as a $100 million-plus opportunity, the procedures are still in early rollout phase—with only a pilot for skin excision completed in Q4 2025 and stand-alone skin tightening deployed in the second half of 2025—meaning revenue contribution remains minimal and uncertain. The assumption that GLP-1 users will seek these specific aesthetic services assumes a durable behavioral shift, yet there is no evidence that patients maintain long-term engagement with aesthetic providers post-weight loss, especially if they achieve their goals or face side effects from medication. Furthermore, the aesthetics industry is highly fragmented with low barriers to entry, and competitors—including medspas, plastic surgery clinics, and new entrants—are rapidly adopting similar GLP-1-adjacent service offerings, potentially eroding AirSculpt's first-mover advantage. The company's marketing spend, while enhanced, is still tied to discretionary consumer spending, which remains sensitive to economic downturns, and the fact that 50% of patients use third-party financing (with full upfront payment to AirSculpt but recourse risk to lenders) suggests underlying affordability constraints that could worsen if interest rates remain elevated or consumer confidence declines. The guidance for Q1 2026 revenue indicating a slight year-over-year decline, despite full-year expectations of modest growth, implies a back-end loaded recovery that may not materialize if seasonal trends or external shocks disrupt the anticipated inflection point.
AirSculpt's operational turnaround remains fragile and dependent on sustained cost discipline that may not be durable, as the company's recent margin improvements are largely driven by one-time SG&A reductions rather than structural revenue growth, leaving it vulnerable to margin compression if topline expansion stalls. The Q4 2025 adjusted EBITDA increase of $0.6 million was driven by gross margin expansion (to ~59%) and a $5 million decline in SG&A—largely from cost initiatives taken throughout 2025—yet revenue still declined 15% year-over-year and 16% on a same-store basis, indicating that the business is not yet generating organic growth at the center level. While management cites improved lead and consult volumes converting to revenue, the lack of specific metrics on conversion rates or average transaction size leaves room for skepticism about the sustainability of the volume trend. The decision to pause de novo center openings in 2026 to focus on existing base growth tacitly acknowledges uncertainty in replicating unit-level economics at new locations, and the exit of the sole international clinic (London) underscores challenges in scaling beyond the current footprint. Furthermore, the helium plasma supply constraint—where a meaningful portion of global supply is offline due to the Iran conflict—poses a tangible risk to the core skin tightening service, which management acknowledges they are monitoring but have not quantified in terms of potential downtime or cost impact. The company's leverage ratio, while improved to below 2.5x, remains dependent on continued debt paydown and refinancing success, and any delay in securing favorable terms could strain liquidity, especially given that cash flow from operations was only $3.1 million for the full year 2025 versus $11.4 million in 2024. This weak cash generation, combined with a business model that requires upfront investment in marketing and talent to drive volume, creates a scenario where AirSculpt could struggle to fund both balance sheet repair and growth initiatives simultaneously if revenue momentum fails to accelerate as expected.